Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

Inclusion Criteria:

- Patients aged 18 years or older

- Newly diagnosed advanced (stage IV) /recurrent non-squamous NSCLC for which they had
not received any systemic anti-cancer therapy for metastatic disease

- Histologically or cytologically confirmed diagnosis of predominantly non-squamous
NSCLC

- Existence of at least 1 measurable lesion by RECIST v1.1

- Adequate hematological, renal and liver function

- Eastern Collaborative Oncology Group Performance Status (ECOG PS) 0 or 1

- Life expectancy longer than 6 months

Exclusion Criteria:

- Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and
mixed adenosquamous carcinomas of predominantly squamous nature

- Any unresolved toxicities from prior systemic therapy

- Known sensitizing EGFR mutations or EML4-ALK translocation positive mutations

- Previous dosing with vascular endothelial growth factor (VEGF) inhibitor

- Known hypersensitivity to any excipients of the Investigational Products (IPs) and
combination chemotherapy

- Use of prohibited concomitant medication

- Known Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection

- Fertile men or women of childbearing potential not using adequate contraception.

Other inclusion/exclusion criteria may apply.